1H-imidazo [4, 5-B] pyridyl nitrogen mustard derivative as well as preparation method and application thereof
Preparation of 1H-imidazo[4,5-B]pyridyl nitrogen mustard derivatives through simplified synthesis methods, solving the problems of complex synthesis and cumbersome isolation and purification in the prior art, and achieving significant pharmacology of this compound in the field of anti-tumor Activity, especially in inhibiting tumor cell proliferation.
Patent Information
- Application Number
- CN202411222572.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-09-02
AI Technical Summary
The synthesis method of 1H-imidazo[4,5-B] pyridine derivatives is complex and the isolation and purification is complicated, which affects its application in anti-tumor drugs.
Using 2,3-diaminopyridine and 4-[bis(β-chloroethyl)amino]benzaldehyde as raw materials, the synthesis step was simplified to obtain 1H-imidazolo[4, 5-B] Pyridyl nitrogen mustard derivative.
A simplified synthesis and isolation process was achieved. In vitro experiments showed that the compound had significant anti-tumor activity, especially in inhibiting tumor cell proliferation, and had extensive research and development value.
Smart Images

Figure CN119019393A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of pharmaceutical intermediates and anti-tumor drugs, and in particular to a 1H-imidazo[4,5-B]pyridyl nitrogen mustard derivative and a preparation method and application thereof. Background Art
[0002] 1H-Imidazolo[4,5-B]pyridine derivatives play an important role in anti-tumor, anti-viral and anti-bacterial applications, but their synthesis methods are difficult and separation and purification are cumbersome. At the same time, the substituents on the ring have different degrees of influence on the activity, and the modification sites are mainly 2, 5, 6 and 7. Nitrogen mustard is an important class of anti-tumor substances. The different carrier parts to which it is connected have a great influence on the overall physicochemical properties and physiological activity of the compound. Therefore, it is crucial to provide anti-tumor drugs with simple and easy synthesis methods. Summary of the invention
[0003] The purpose of the present invention is to provide a 1H-imidazo[4,5-B]pyridyl nitrogen mustard derivative and its preparation method and application, so as to solve the problems existing in the above-mentioned prior art. The present invention uses 1H-imidazo[4,5-B]pyridine and nitrogen mustard functional groups for splicing to synthesize new derivatives. The synthesis method is simple and easy, and the separation is simple. The prepared target molecules have good anti-tumor activity and show strong pharmacological activity in inhibiting tumor cell proliferation.
[0004] To achieve the above object, the present invention provides the following solutions:
[0005] One of the technical solutions of the present invention is a 1H-imidazo[4,5-B]pyridinyl nitrogen mustard derivative, the structural formula of which is shown in Formula I:
[0006]
[0007] Wherein, R1, R2 and R3 are selected from any one of hydrogen, halogen or methyl.
[0008] The second technical solution of the present invention is a method for preparing the 1H-imidazo[4,5-B]pyridinyl nitrogen mustard derivative, comprising the following steps: adding substituted 2,3-diaminopyridine, 4-[bis(β-chloroethyl)amino]benzaldehyde and a catalyst to a solvent, heating the reaction, and then separating and purifying the reaction product by thin layer chromatography to obtain the 1H-imidazo[4,5-B]pyridinyl nitrogen mustard derivative.
[0009] The third technical solution of the present invention is the use of the 1H-imidazo[4,5-B]pyridyl nitrogen mustard derivative in the preparation of anti-tumor drugs, wherein the tumor is colorectal adenocarcinoma or renal clear cell adenocarcinoma.
[0010] A fourth technical solution of the present invention is an anti-tumor drug, comprising the 1H-imidazo[4,5-B]pyridyl nitrogen mustard derivative.
[0011] Based on the above technical solution, the present invention has the following technical effects:
[0012] The present invention uses substituted 2,3-diaminopyridine and 4-[bis(β-chloroethyl)amino]benzaldehyde as raw materials, and obtains the target molecule in one step through a condensation reaction. Currently, the synthesis of 1H-imidazo[4,5-B]pyridine compounds requires multiple steps, and separation and purification are cumbersome, while the present invention only requires one step of synthesis, and the separation method is simple. In vitro anti-tumor experiments show that the synthesized target compounds all have obvious anti-tumor effects, show strong pharmacological activity in inhibiting tumor cell proliferation, and have extensive research and development value in the field of anti-tumor drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0014] Figure 1 This is a graph showing the experimental results of the anti-proliferation activity of the product 1a prepared in Example 1 of the present invention on SW620 cells and 786-O cells.
[0015] Figure 2 This is a graph showing the experimental results of the anti-proliferation activity of the product 1b prepared in Example 2 of the present invention on SW620 cells and 786-O cells.
[0016] Figure 3 This is a graph showing the experimental results of the anti-proliferation activity of the product 1c prepared in Example 3 of the present invention on SW620 cells and 786-O cells.
[0017] Figure 4 This is a graph showing the experimental results of the anti-proliferation activity of product 1d prepared in Example 4 of the present invention on SW620 cells and 786-O cells.
[0018] Figure 5 This is a graph showing the experimental results of the anti-proliferation activity of the product 1e prepared in Example 5 of the present invention on SW620 cells and 786-O cells.
[0019] Figure 6 This is a graph showing the experimental results of the anti-proliferation activity of the product 1f prepared in Example 6 of the present invention on SW620 cells and 786-O cells. DETAILED DESCRIPTION
[0020] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0021] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0022] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0023] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present application description and examples are exemplary only.
[0024] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0025] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art, and the reagents or raw materials used, unless otherwise specified, are purchased from commercial channels or have been disclosed.
[0026] The embodiment of the present invention provides a 1H-imidazo[4,5-B]pyridyl nitrogen mustard derivative, the structural formula of which is shown in Formula I:
[0027]
[0028] Wherein, R1, R2 and R3 are selected from any one of hydrogen, halogen or methyl.
[0029] In some specific embodiments, the 1H-imidazo[4,5-B]pyridinyl nitrogen mustard derivative is:
[0030]
[0031]
[0032] The present invention also provides a method for preparing the 1H-imidazo[4,5-B]pyridinyl nitrogen mustard derivative, comprising the following steps: adding substituted 2,3-diaminopyridine, 4-[bis(β-chloroethyl)amino]benzaldehyde and a catalyst to a solvent, heating the mixture for reaction, and separating and purifying the reaction product by thin layer chromatography to obtain the 1H-imidazo[4,5-B]pyridinyl nitrogen mustard derivative.
[0033] In some specific embodiments, the molar ratio of the substituted 2,3-diaminopyridine to 4-[bis(β-chloroethyl)amino]benzaldehyde is 1:1.
[0034] In some specific embodiments, the solvent is N,N-dimethylformamide or N,N-dimethylacetamide.
[0035] In some specific embodiments, the catalyst is propionic acid or p-toluenesulfonic acid.
[0036] In some specific embodiments, the heating reaction is carried out at a temperature of 120° C. to 160° C. for 5 to 12 hours.
[0037] In some specific embodiments, the mobile phase of the thin layer chromatography is dichloromethane:ethyl acetate=1:3-1:6 (V / V).
[0038] The embodiment of the present invention also provides the use of the 1H-imidazo[4,5-B]pyridyl nitrogen mustard derivative in the preparation of an anti-tumor drug, wherein the tumor is colorectal adenocarcinoma or renal clear cell adenocarcinoma.
[0039] The embodiment of the present invention further provides an anti-tumor drug, comprising the 1H-imidazo[4,5-B]pyridyl nitrogen mustard derivative.
[0040] In some specific embodiments, a pharmaceutically acceptable excipient is also included.
[0041] The invention synthesizes a 1H-imidazo[4,5-B]pyridyl nitrogen mustard derivative by condensing an ortho-diamino group on an aromatic heterocycle with a formyl group containing an aromatic nitrogen mustard, that is, an aromatic nitrogen mustard is introduced at the 2-position of 1H-imidazo[4,5-B]pyridine, and different substituents are provided at the 5-, 6- and 7-positions. The reaction is completed in one step, and the post-processing is simple. The product shows an obvious effect in inhibiting the proliferation of tumor cells and has a wide range of application value.
[0042] Example 1
[0043] The structural formula of compound 1a is as follows:
[0044]
[0045] Preparation of compound 1a:
[0046] 2,3-Diamino-4-chloropyridine (1 mmol) and 4-[bis(β-chloroethyl)amino]benzaldehyde (1 mmol) were added to N,N-dimethylacetamide (13 mL), p-toluenesulfonic acid (0.1 mmol) was added, and the mixture was heated at 150°C for 8 hours. The reaction solution was added to 50 mL of water, filtered, washed with water, and freeze-dried. The crude product was then separated and purified by thin layer chromatography to obtain product 1a, and the mobile phase was dichloromethane:methanol=80:1 (V / V).
[0047] Characterization data: 1 H NMR (600MHz, DMSO-d6) δ: 13.11 (s, 1H, NH), 8.20 (d, 1H, J = 5.32Hz, Pyridine-H); 8.13 (d, 2H, J = 8.90 Hz, ArH), 7.32 (d, 1H, J = 5.32Hz, Pyridine-H), 6.96 (d, 2H, J = 8.90Hz, ArH), 3.89-3.80 (m, 8H, CH2). 13 C NMR(150MHz,DMSO-d6)δ:149.01,142.43,129.97,118.08,117.65,110.99,51.71,43.21.HR-MS(ESI)calcd for C 16 H 16 Cl3N4[M+H] + 369.0441, found 369.0442.
[0048] Example 2
[0049] The structural formula of compound 1b is as follows:
[0050]
[0051] Preparation of compound 1b:
[0052] 2,3-Diamino-5-chloropyridine (1 mmol) and 4-[bis(β-chloroethyl)amino]benzaldehyde (1 mmol) were added to N,N-dimethylacetamide (13 mL), p-toluenesulfonic acid (0.1 mmol) was added, and the mixture was heated at 150°C for 8 hours. The reaction solution was added to 50 mL of water, filtered, washed with water, and freeze-dried. The crude product was then separated and purified by thin layer chromatography to obtain product 1b. The mobile phase was dichloromethane:methanol = 80:1 (V / V).
[0053] Characterization data: 1 H NMR (600MHz, DMSO-d6) δ: 8.25 (d, 1H, J = 2.30, Pyridine-H); 8.10 (d, 2H, J = 8.90, ArH) ,8.00(d,1H,J=2.30,Pyridine-H),6.94(d,2H,J=8.90,ArH),3.88-3.79(m,8H,CH2). 13 C NMR(150MHz,DMSO-d6)δ:156.36,148.85,141.02,128.96,124.20,122.41,118.24,112.28,51.88,43.29.HR-MS(ESI)calcd for C 16 H 16 Cl3N4[M+H] + 369.0441, found 369.0439.
[0054] Example 3
[0055] The structural formula of compound 1c is as follows:
[0056]
[0057] Preparation of compound 1c:
[0058] 2,3-Diamino-6-chloropyridine (1 mmol) and 4-[bis(β-chloroethyl)amino]benzaldehyde (1 mmol) were added to N,N-dimethylacetamide (13 mL), p-toluenesulfonic acid (0.1 mmol) was added, and the mixture was heated at 150°C for 8 hours. The reaction solution was added to 50 mL of water, filtered, washed with water, and freeze-dried. The crude product was then separated and purified by thin layer chromatography to obtain product 1c. The mobile phase was dichloromethane:methanol=80:1 (V / V).
[0059] Characterization data: 1 H NMR (600MHz, DMSO-d6) δ: 7.98 (d, 2H, J = 8.96, ArH), 7.85 (d, 1H, J = 8.42Hz, Pyridine-H), 7.15 (d, 1H ,J=8.42,Pyridine-H),6.87(d,1H,J=8.96,ArH),6.94(d,2H,J=8.90,ArH),3.79-3.70(m,8H,CH2). 13C NMR(150MHz,DMSO-d6)δ:156.14,148.95,144.77,128.89,118.78,111.90,52.83,41.51.HR-MS(ESI)calcd for C 16 H 16 Cl3N4[M+H] + 369.0441, found 369.0443.
[0060] Example 4
[0061] The structural formula of compound 1d is as follows:
[0062]
[0063] Preparation of compound 1d:
[0064] 2,3-Dichloro-5-bromo-6-methylpyridine (1 mmol) and 4-[bis(β-chloroethyl)amino]benzaldehyde (1 mmol) were added to N,N-dimethylacetamide (13 mL), p-toluenesulfonic acid (0.1 mmol) was added, and the mixture was heated at 150°C for 8 hours. The reaction solution was added to 50 mL of water, filtered, washed with water, and freeze-dried. The crude product was then separated and purified by thin layer chromatography to obtain product 1d, with the mobile phase being dichloromethane:methanol=80:1 (V / V).
[0065] Characterization data: 1 H NMR (600MHz, DMSO-d6) δ: 8.12 (s, 1H, Pyridine-H), 8.06 (d, 2H, J = 8.92Hz, Ar-H), 6.94 (d, 2H, J = 8.92, Ar-H), 3.88-3.79 (m, 8H, CH2), 2.66 (s, 3H, CH3). 13 CNMR(150MHz,DMSO-d6)δ:148.13,127.98,117.85,113.86,111.61,52.30,43.21,25.37.HR-MS(ESI)calcd for C 17 H 18 BrCl2N4[M+H] + 427.0092, found 427.0095.
[0066] Example 5
[0067] The structural formula of compound 1e is as follows:
[0068]
[0069] Preparation of compound 1e:
[0070] 2,3-Dichloro-5-bromo-4-methylpyridine (1 mmol) and 4-[bis(β-chloroethyl)amino]benzaldehyde (1 mmol) were added to N,N-dimethylacetamide (13 mL), p-toluenesulfonic acid (0.1 mmol) was added, and the mixture was heated at 150°C for 8 hours. The reaction solution was added to 50 mL of water, filtered, washed with water, and freeze-dried. The crude product was then separated and purified by thin layer chromatography to obtain product 1e, and the mobile phase was dichloromethane:methanol=80:1 (V / V).
[0071] Characterization data: 1 H NMR (600MHz, DMSO-d6) δ: 8.30 (s, 1H, Pyridine-H), 8.11 (d, 2H, J = 8.93Hz, Ar-H), 6.94 (d, 2H, J = 8.93, Ar-H), 3.88-3.79 (m, 8H, CH2), 2.64 (s, 3H, CH3). 13 CNMR(150MHz,DMSO-d6)δ:147.85,144.55,128.92,118.21,116.53,111.19,53.04,44.56,15.68.HR-MS(ESI)calcd for C 17 H 18 BrCl2N4[M+H] + 427.0092, found 427.0095.
[0072] Example 6
[0073] The structural formula of compound 1f is as follows:
[0074]
[0075] Preparation of compound 1f:
[0076] 2,3-Dichloropyridine (1mmol) and 4-[bis(β-chloroethyl)amino]benzaldehyde (1mmol) were added to N,N-dimethylacetamide (13mL), p-toluenesulfonic acid (0.1mmol) was added, and the mixture was heated at 150°C for 8 hours. The reaction solution was added to 50mL of water, filtered, washed with water, and freeze-dried. The crude product was then separated and purified by thin layer chromatography to obtain product 1f, with the mobile phase being dichloromethane:methanol=80:1 (V / V).
[0077] Characterization data: 1H NMR(600MHz,DMSO-d6)δ:13.22(s,1H,NH),8.22(s,1H,Pyridine-H),8.08(d,2H,J=8.90Hz,ArH),7.91(s,1H,P yridine-H), 7.18 (dd, J=7.88, 4.802Hz, 1H, Pyridine-H), 6.93 (d, 2H, J=8.90Hz, ArH), 3.86-3.78 (m, 8H, CH2). 13 C NMR(150MHz,DMSO-d6)δ:167.03,153.59,150.12,148.76,143.04,136.44,128.81,125.64,118.26,112.37,52.37,41.60.HR-MS(ESI)calcd for C 16 H 17 Cl2N4[M+H] + 335.0830, found 335.0833.
[0078] Effect example
[0079] In vitro antiproliferative activity
[0080] When the tumor cells (SW620 and 786-O) were in the logarithmic growth phase, approximately 2×10 3 After 24 hours of cell attachment, add 100 μM of different concentrations of drugs diluted in culture medium containing 10% FBS to each well and put it into the 37°C incubator again. After 72 hours of cell culture, add 25 μL MTT reagent to each well and incubate in the incubator for 3 hours. Discard the culture medium in the 96-well plate, dissolve it with DMSO, and read the OD of each well with an enzyme reader. 570 The survival rate of cells after treatment with different drug concentrations was calculated.
[0081] Cell survival rate % = [(Abs 样品 -Abs 背景 ) / (Abs 阴性对照 -Abs 背景 )]×100%;
[0082] Among them, Abs 样品 : absorbance when the test compound is added; Abs 背景 : Absorbance without cells and detected compounds; Abs 阴性对照 : Absorbance without the detected compound.
[0083] The results of the antiproliferative activities of the products 1a to 1f prepared in Examples 1 to 6 on SW620 cells and 786-O cells are shown in Figures 1 to 6 . As can be seen from the figure, with the increase of compound concentration, its anti-proliferation ability on SW620 cells and 786-O cells continued to increase, and all showed good anti-proliferation activity. Among them, 1c had the strongest activity and showed the best anti-proliferation ability on SW620 cells and 786-O cells, with half-inhibitory concentrations of 14.1μM and 12.5μM, respectively. 1b was second in activity, with half-inhibitory concentrations of 22.2μM and 20.8μM, respectively. Next came 1a, 1d and 1e, and 1f was less active than other compounds.
[0084] It can be seen that the activity of chlorine-containing compounds is stronger than that of non-substituted compounds and bromine and methyl-substituted compounds. At the same time, the activity of chlorine-substituted compounds at position 5 is stronger than that of substituted compounds at positions 6 and 7. Regarding the antiproliferative ability of the compounds on the two cell lines, the antiproliferative ability of 786-O is stronger than that of SW620.
[0085] The above results indicate that the synthesized 1H-imidazo[4,5-B]pyridinyl nitrogen mustard derivatives have significant antitumor activity.
[0086] Obviously, the above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the implementation methods of the present invention. For ordinary technical users in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.
Claims
1. A 1H-imidazo[4,5-B]pyridinyl nitrogen mustard derivative, characterized in that: Its structural formula is shown in Formula I: Wherein, R1, R2 and R3 are selected from any one of hydrogen, halogen or methyl.
2. The method for preparing the 1H-imidazo[4,5-B]pyridinyl nitrogen mustard derivative according to claim 1, characterized in that: The following steps are involved: Substituted 2,3-diaminopyridine, 4-[bis(β-chloroethyl)amino]benzaldehyde and a catalyst are added to a solvent, heated for reaction, and the reaction product is separated and purified by thin layer chromatography to obtain the 1H-imidazo[4,5-B]pyridyl nitrogen mustard derivative.
3. The preparation method according to claim 2, characterized in that: The molar ratio of the substituted 2,3-diaminopyridine to 4-[bis(β-chloroethyl)amino]benzaldehyde is 1:
1.
4. The preparation method according to claim 2, characterized in that: The solvent is N,N-dimethylformamide or N,N-dimethylacetamide.
5. The preparation method according to claim 2, characterized in that: The catalyst is propionic acid or p-toluenesulfonic acid.
6. The preparation method according to claim 2, characterized in that: The temperature of the heating reaction is 120° C. to 160° C., and the time is 5 to 12 hours.
7. The preparation method according to claim 2, characterized in that: The mobile phase of the thin layer chromatography is dichloromethane:ethyl acetate=1:3-1:6 (V / V).
8. The use of the 1H-imidazo[4,5-B]pyridinyl nitrogen mustard derivative as claimed in claim 1 in the preparation of anti-tumor drugs, characterized in that: The tumor is colorectal adenocarcinoma or renal clear cell adenocarcinoma.
9. An anti-tumor drug, characterized in that: The invention comprises the 1H-imidazo[4,5-B]pyridinyl nitrogen mustard derivative as described in claim 1.
10. The anti-tumor drug according to claim 9, characterized in that: Pharmaceutically acceptable excipients are also included.
Citation Information
Patent Citations
Chlormethine-containing imidazole heterocyclic derivative, preparation method and application thereof
CN113387892A
Novel DNA-targeted alkylating agents
WO1996006831A1
N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
WO2010138820A2
